Dennis M. Mcgrath - 11 Sep 2025 Form 4 Insider Report for DarioHealth Corp. (DRIO)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
15 Sep 2025, 16:06:48 UTC
Prior SEC filing
21 Feb 2025
Next SEC filing
01 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Dennis M. McGrath

Key filing fact

Dennis M. Mcgrath filed Form 4 for DarioHealth Corp. (DRIO) on 15 Sep 2025.

Key facts

  • This page summarizes Dennis M. Mcgrath's Form 4 filing for DarioHealth Corp. (DRIO).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 15 Sep 2025, 16:06.

Change

  • Previous filing in this sequence was filed on 21 Feb 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001269340 Primary reporting owner

MCGRATH DENNIS M

Relationship
Director
Address
322 W 57TH STREET, #33B18, NEW YORK
Signature
/s/ Dennis M. McGrath
Signature date
15 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DRIO transaction

Common Stock

Award

Transaction value
$0
Shares
+20,000
Change %
+258%
Price
$0.000000
Shares after
27,737
Date
11 Sep 2025
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The restricted share award shall vest on the last day of the second-year anniversary after the grant date.

Footnote F2

The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .